– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 development of Descartes-08 for MG – – Combined company to be led by Carsten Brunn, Ph.D.; Cartesian Co-Founders Murat Kalayoglu, M.D., Ph.D., and Michael Singer, M.D., Ph.D., to serve on Board of Directors – – Legacy Selecta stockholders to receive transferable Contingent Value Rights (CVRs) entitling holders to receive future royalties and milestone payments related to SEL-212 and all other legacy Selecta assets – – Company to host conference call today at 9:00 a.m.

-合并创建了一个完全整合的，上市公司开创性的RNA细胞疗法治疗自身免疫性疾病-笛卡尔的垄断管道包括第二阶段领先资产Descartes-08，在重症肌无力（MG）-多种近期催化剂，包括预计在2024年中期以MG进行的Descartes-08 2b期研究的数据以及在其他自身免疫适应症中启动多项研究-预计合并公司将获得超过1.1亿美元的备考现金余额，其中包括6025美元来自同时进行的私人融资；MG–-联合公司的Descartes-08第3阶段开发的预期现金跑道由Carsten Brunn博士领导。；笛卡尔联合创始人Murat Kalayoglu，医学博士，哲学博士，Michael Singer，医学博士，哲学博士，担任董事会-遗产Selecta股东，获得可转让的或有价值权利（CVRs），有权获得与SEL-212和所有其他遗产Selecta资产相关的未来版税和里程碑付款-今天上午9:00，公司主办电话会议。

ET – WATERTOWN, Mass. and GAITHERSBURG, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) (the Company) today announced that it has merged with Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering RNA cell therapies for autoimmune diseases. In connection with the merger, Selecta announced a $60.25 million private financing led by Timothy A.

ET-WATERTOWN，MA。和GAITHERSBURG，Md，2023年11月13日（GLOBE NEWSWIRE）-Selecta Biosciences，Inc。（纳斯达克股票代码：SELB）（该公司）今天宣布与笛卡尔治疗公司合并。，一家临床阶段生物技术公司，开创了自身免疫性疾病的RNA细胞疗法。在合并过程中，Selecta宣布了由Timothy a.领导的6025万美元私人融资。

Springer, Ph.D., member of the Selecta Board of Directors. With the cash from both companies at closing and the proceeds of the concurrent private financing, the combined company is expected to have over $110 million on hand to support th.

Springer博士，Selecta董事会成员。随着两家公司在关闭时的现金以及同时进行的私人融资的收益，合并公司预计将拥有超过1.1亿美元来支持th。